Kidney Transplant CMV Prevention
This study is looking at ways to prevent cytomegalovirus (CMV) disease in adults who have received a kidney transplant. CMV is a common virus that can cause problems after a transplant. The study compares two approaches: "preemptive therapy" where you receive Valganciclovir only if CMV is detected, and "prophylaxis" where you receive Valganciclovir daily for 200 days after transplant to prevent CMV from developing. You can join if you are 18 or older, have had a kidney transplant, and tested negative for CMV antibodies before or shortly after your transplant. The main goal is to see how many people in each group develop CMV disease within one year after their transplant. The study is currently recruiting about 360 participants.
- Study design
- This is a randomized, multicenter study comparing two different treatment approaches. About 360 participants will be assigned by chance to one of the two groups.
- What's involved
- You would receive either Valganciclovir daily for 200 days or undergo weekly blood tests for 100 days, receiving Valganciclovir only if CMV is detected.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year after their transplant to check for CMV disease.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
At a glance
Conditions
Where it's being run
5 sites across 5 statesStudy leadership
- Abhijit P. Limaye, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of endpoint committee (EC)-confirmed CMV disease (either syndrome or end-organ) by 1-year post-transplant.Within 1-year post-transplant